What is HC Wainwright's Forecast for Senseonics Q4 Earnings?

Senseonics Holdings, Inc. (NYSE:SENS - Free Report) - Research analysts at HC Wainwright lowered their Q4 2025 earnings per share (EPS) estimates for shares of Senseonics in a note issued to investors on Thursday, August 7th. HC Wainwright analyst S. Lee now expects that the company will earn ($0.02) per share for the quarter, down from their previous forecast of ($0.01). HC Wainwright has a "Buy" rating and a $1.40 price target on the stock. The consensus estimate for Senseonics' current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Senseonics' Q1 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.06) EPS, FY2027 earnings at ($0.03) EPS, FY2028 earnings at ($0.01) EPS and FY2029 earnings at $0.02 EPS.

Other analysts also recently issued research reports about the company. Lake Street Capital upgraded Senseonics to a "strong-buy" rating in a research note on Thursday, July 17th. TD Cowen began coverage on Senseonics in a research note on Tuesday, July 15th. They set a "buy" rating and a $1.25 target price for the company. Finally, Wall Street Zen upgraded Senseonics to a "sell" rating in a research note on Monday, May 12th. One research analyst has rated the stock with a sell rating, two have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $1.55.

Senseonics Stock Performance

NYSE:SENS traded up $0.00 during mid-day trading on Monday, hitting $0.48. 799,640 shares of the company's stock traded hands, compared to its average volume of 8,255,172. The firm has a 50 day moving average of $0.51 and a two-hundred day moving average of $0.65. Senseonics has a 12 month low of $0.25 and a 12 month high of $1.40. The firm has a market capitalization of $315.99 million, a price-to-earnings ratio of -3.72 and a beta of 0.88. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17.

Hedge Funds Weigh In On Senseonics

Several large investors have recently added to or reduced their stakes in SENS. Beck Mack & Oliver LLC boosted its stake in Senseonics by 16.5% in the 2nd quarter. Beck Mack & Oliver LLC now owns 176,950 shares of the company's stock valued at $84,000 after buying an additional 25,000 shares in the last quarter. IFP Advisors Inc boosted its stake in Senseonics by 120.9% in the 1st quarter. IFP Advisors Inc now owns 47,500 shares of the company's stock valued at $31,000 after buying an additional 26,000 shares in the last quarter. CTC Alternative Strategies Ltd. acquired a new stake in Senseonics in the 1st quarter valued at $31,000. Raymond James Financial Inc. acquired a new stake in Senseonics in the 4th quarter valued at $26,000. Finally, Smith Salley Wealth Management acquired a new stake in Senseonics in the 1st quarter valued at $36,000. Institutional investors and hedge funds own 12.36% of the company's stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.